Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
Status:
Completed
Trial end date:
2015-01-31
Target enrollment:
Participant gender:
Summary
It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in
maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium
levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was
established during the open-label acute phase versus no difference between each ZS dose
(highest to lowest) versus placebo control (null hypothesis).